High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa - 14/01/19
Doi : 10.1016/j.jaad.2018.06.028
Angelique Rondags, MD a, ⁎ 
, Kelsey R. van Straalen, MD b, Suzanne Arends, PhD c, Hessel H. van der Zee, MD, PhD b, Errol P. Prens, MD, PhD b, Anneke Spoorenberg, MD, PhD c, Barbara Horváth, MD, PhD a
, Kelsey R. van Straalen, MD b, Suzanne Arends, PhD c, Hessel H. van der Zee, MD, PhD b, Errol P. Prens, MD, PhD b, Anneke Spoorenberg, MD, PhD c, Barbara Horváth, MD, PhD a a Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
b Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands
c Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands
∗Correspondence to: Angelique Rondags, MD, Department of Dermatology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The NetherlandsDepartment of DermatologyUniversity Medical Center GroningenPO Box 30.0019700 RBGroningenThe Netherlands
| Funding sources: None. |
|
| Conflicts of interest: Dr Rondags has no conflicts of interests to declare. Dr Van Straalen has no conflicts of interests to declare. Dr Arends reports a grant/research support from Pfizer outside the submitted work. Dr Van der Zee reports consultation and advisory from Abbvie and InflaRX outside the submitted work. Dr Prens reports honoraria from AbbVie, Amgen, Celgene, Janssen, Galderma, Novartis, and Pfizer for participation as a speaker and on advisory boards and received investigator-initiated grants (paid to Erasmus MC) from AbbVie, AstraZeneca, Janssen, and Pfizer outside the submitted work. Dr Spoorenberg reports a grant/research support from AbbVie, Pfizer, and UCB and fees from AbbVie, Pfizer, MSD, UCB, and Novartis for consulting and advisory board participation outside the submitted work. Dr Horváth reports fees from AbbVie, Novartis, UCB Pharma, Solenne BV, and Janssen-Cilag for consulting and advisory board participation, scientific research, congress, and courses and fees from Novartis for consulting and advisory board participation, scientific research, and congress outside the submitted work. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 2
P. 551 - février 2019 Retour au numéro
Article précédent
- Atopic dermatitis is associated with osteoporosis and osteopenia in older adults
- Mohammed S. Shaheen, Jonathan I. Silverberg
- Chronic nonmelanoma skin cancers and health-related impairment: A case-control study
- Adam Sutton, Ashley Crew, Shauna Higgins, Andrew Kwong, Ashley Wysong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?